- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
BCG Matrix and VRIO Framework for Genzyme Corp Strategic Challenges with Ceredase
Posted by Sophia Morgan on Jul-30-2018
BCG Matrix
The BCG matrix is a strategic management tool that was created by the Boston Consulting Group, which helps in analysing the position of a strategic business unit and the potential it has to offer. The matrix consists of 4 classifications that are based on two dimensions. These first of these dimensions is the industry or market growth. The other of these dimensions is the relative market share of the strategic business unit. Strategic business units are placed in one of these 4 classifications. The BCG matrix for Genzyme Corp Strategic Challenges with Ceredase will help decide on the strategies that can be implemented for its strategic business units.
Strategic business units with high market growth rate and high relative market share are called stars. Businesses should invest in their stars and can implement vertical integration, market penetration, product development, market development, and horizontal integration strategies. Strategic business units with high market growth rate and low relative market share are called question marks. These strategic business units require close considerations whether the business should continue with them or divest. Strategic business units with low market growth rate but with high relative market share are called cash cows. The business should invest in these to maintain their relative market share. Lastly, the strategic business units with low market growth rate and low relative market share are called dogs. The business should divest these strategic business units.
BCG Matrix of Genzyme Corp Strategic Challenges with Ceredase
The BCG Matrix for Genzyme Corp Strategic Challenges with Ceredase will help Genzyme Corp Strategic Challenges with Ceredase in implementing the business level strategies for its business units. The analysis will first identify where the strategic business units of Genzyme Corp Strategic Challenges with Ceredase fall within the BCG Matrix for Genzyme Corp Strategic Challenges with Ceredase.
Stars
- The financial services strategic business unit is a star in the BCG matrix of Genzyme Corp Strategic Challenges with Ceredase. It operates in a market that shows potential in the future. Genzyme Corp Strategic Challenges with Ceredase earns a significant amount of its income from this SBU. Genzyme Corp Strategic Challenges with Ceredase should vertically integrate by acquiring other firms in the supply chain. This will help it in earning more profits as this Strategic business unit has potential.
- The Number 1 brand Strategic business unit is a star in the BCG matrix of Genzyme Corp Strategic Challenges with Ceredase, and this is also the product that generates the greatest sales amongst its product portfolio. The potential within this market is also high as consumers are demanding this and similar types of products. Genzyme Corp Strategic Challenges with Ceredase should undergo a product development strategy for this SBU, where it develops innovative features on this product through research and development. This will help Genzyme Corp Strategic Challenges with Ceredase by attracting more customers and increases its sales.
- The Number 2 brand Strategic business unit is a star in the BCG matrix of Genzyme Corp Strategic Challenges with Ceredase as Genzyme Corp Strategic Challenges with Ceredase has a 20% market share in this category. It also the market leader in this category. The overall category is expected to grow at 5% in the next 5 years, which shows that the market growth rate is expected to remain high. Genzyme Corp Strategic Challenges with Ceredase should use its current products to penetrate the market. This could be done by improving its distributions that will help in reaching out to untapped areas. This will help increase the sales of Genzyme Corp Strategic Challenges with Ceredase.
Cash Cows
- The supplier management service strategic business unit is a cash cow in the BCG matrix of Genzyme Corp Strategic Challenges with Ceredase. This has been in operation for over decades and has earned Genzyme Corp Strategic Challenges with Ceredase a significant amount in revenue. The market share for Genzyme Corp Strategic Challenges with Ceredase is high, but the overall market is declining as companies manage their supplier themselves rather than outsourcing it. The recommended strategy for Genzyme Corp Strategic Challenges with Ceredase is to stop further investment in this business and keep operating this strategic business unit as long as its profitable.
- The Number 3 brand strategic business unit is a cash cow in the BCG matrix of Genzyme Corp Strategic Challenges with Ceredase. This is an innovative product that has a market share of 25% in its category. Genzyme Corp Strategic Challenges with Ceredase is also the market leader in this category. The overall category has been declining slowly in the past few years. Genzyme Corp Strategic Challenges with Ceredase has the power to influence the market as well in this category. It should, therefore, invest in research and development so that the brand could be innovated. This will help the category grow and will turn this cash cow into a star. The overall benefit would be an increase in sales of Genzyme Corp Strategic Challenges with Ceredase.
- The international food strategic business unit is a cash cow in the BCG matrix for Genzyme Corp Strategic Challenges with Ceredase. This business unit has a high market share of 30% within its category, but people are now inclined less towards international food. This change in trends has led to a decline in the growth rate of the market. The recommended strategy for Genzyme Corp Strategic Challenges with Ceredase is to invest enough to keep this strategic business unit under operations. If it no longer remains profitable and turns into a dog, then Genzyme Corp Strategic Challenges with Ceredase should divest this strategic business unit.
Question Marks
- The local foods strategic business unit is a question mark in the BCG matrix for Genzyme Corp Strategic Challenges with Ceredase. The recent trends within the market show that consumers are focusing more towards local foods. Therefore, this market is showing a high market growth rate. However, Genzyme Corp Strategic Challenges with Ceredase has a low market share in this segment. The recommended strategy for Genzyme Corp Strategic Challenges with Ceredase is to invest in research and development to come up with innovative features. This product development strategy will ensure that this strategic business unit turns into a cash cow and brings profits for the company in the future.
- The Number 4 brand strategic business unit is a question mark in the BCG matrix for Genzyme Corp Strategic Challenges with Ceredase. This strategic business unit is a part of a market that is rapidly growing. However, this strategic business unit has been incurring losses in the past few years. It has also failed in the attempts made at innovation by research and development teams. The recommended strategy for Genzyme Corp Strategic Challenges with Ceredase is to divest and prevent any future losses from occurring.
- The confectionery strategic business unit is a question mark in the BCG matrix for Genzyme Corp Strategic Challenges with Ceredase. The confectionery market is an attractive market that is growing over the years. However, Genzyme Corp Strategic Challenges with Ceredase has a low market share in this attractive market. The low sales are as a result of low reach and poor distribution of Genzyme Corp Strategic Challenges with Ceredase in this segment. The recommended strategy for Genzyme Corp Strategic Challenges with Ceredase is to undergo market penetration, where it pushes to make its product present on more outlets. This will ensure increased sales for Genzyme Corp Strategic Challenges with Ceredase and convert this strategic business unit into a cash cow.
Dogs
- The plastic bags strategic business unit is a dog in the BCG matrix of Genzyme Corp Strategic Challenges with Ceredase. This strategic business unit has been in the loss for the last 5 years. It also operates in a market that is declining due to greater environmental concerns. The recommended strategy for Genzyme Corp Strategic Challenges with Ceredase is to divest this strategic business unit and minimise its losses.
- The Number 5 brand strategic business unit is a dog in the BCG matrix for Genzyme Corp Strategic Challenges with Ceredase. This is operating in a market segment that is declining in the past 5 years. The company also has negative profits for this strategic business unit. However, it is expected that the market will grow in the future with environmental changes that are occurring. The recommended strategy for Genzyme Corp Strategic Challenges with Ceredase is to invest in the business enough to convert into a cash cow. This will ensure profits for Genzyme Corp Strategic Challenges with Ceredase if the market starts growing again in the future.
- The synthetic fibre products strategic business unit is a dog in the BCG matrix of Genzyme Corp Strategic Challenges with Ceredase. The market for such products has been declining, and as a result of this decline, Genzyme Corp Strategic Challenges with Ceredase has been facing a loss in the past 3 years. The market share for it is also less than 5%. The recommended strategy for Genzyme Corp Strategic Challenges with Ceredase is to divest this strategic business unit to minimise any further losses.
- The artificially flavoured products strategic business unit is a dog in the BCG matrix for Genzyme Corp Strategic Challenges with Ceredase. These products were launched recently, with the prediction that this segment would grow. However, with increasing health consciousness, people are now refraining from consumption of artificial flavours. The market is shrinking, and Genzyme Corp Strategic Challenges with Ceredase has no significant market share. The recommended strategy for Genzyme Corp Strategic Challenges with Ceredase is to call back this product.
Some of the strategic business units identified in the BCG matrix for Genzyme Corp Strategic Challenges with Ceredase have the potential of changing from their current classification. For example, a dog changing to a cash cow. These have been identified in the BCG matrix of Genzyme Corp Strategic Challenges with Ceredase and recommended strategies to ensure such change have also been made.
VRIO Framework
The VRIO Framework or VRIO analysis is a strategic management tool that is used to analyse a firm’s internal strengths and resources. It helps identify which one of its internal strengths and resources can be a source of sustained competitive advantage. The analysis is based on the idea that a firm’s internal resources are a source of sustained competitive advantage if they are valuable, rare, cannot be imitated by competition, and are organised to capture value for the organisation. The VRIO analysis requires looking at a firm's resources based on these 4 factors.
Based on the analysis, each resource can either provide a sustained competitive advantage, has a good competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage. A sustained competitive advantage exists when a resource is valuable, rare, non-imitable and organised. A good competitive advantage occurs if it is valuable, rare, and non-imitable. A temporary competitive advantage exists if it is valuable and rare. A competitive parity occurs if it is only valuable. Lastly, the resource is a competitive disadvantage if it is neither of the 4. The analysis takes place in this order by first assessing whether a resource is valuable, rare, imitable and organised.
References
Barney, J. (1991). Firm resources and sustained competitive advantage. Journal of management, 17(1), 99-120.
Barney, J. (2002). Gaining and Sustaining Competitive Advantage, 2nd ed. Prentice Hall, Upper Saddle River, NJ.
Cardeal, N., & Antonio, N. S. (2012). Valuable, rare, inimitable resources and organization (VRIO) resources or valuable, rare, inimitable resources (VRI) capabilities: What leads to competitive advantage?
Hambrick, D. C., MacMillan, I. C., & Day, D. L. (1982). Strategic attributes and performance in the BCG matrix—A PIMS-based analysis of industrial product businesses. Academy of Management Journal, 25(3), 510-531.
Jurevicius, O. (2013a). VRIO Framework. Retrieved from https://www.strategicmanagementinsight.com/tools/vrio.html
Jurevicius, O. (2013b). BCG growth-share matrix. Retrieved from https://www.strategicmanagementinsight.com/tools/bcg-matrix-growth-share.html
Knott, P. J. (2015). Does VRIO help managers evaluate a firm’s resources? Management Decision, 53(8), 1806-1822.
Seeger, J. A. (1984). Research note and communication. Reversing the images of BCG's growth/share matrix. Strategic Management Journal, 5(1), 93-97.
Smith, M. (2002). Derrick's Ice–Cream Company: applying the BCG matrix in customer profitability analysis. Accounting education, 11(4), 365-375.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Jeffrey Chan
5.0
I got errors in the paper that were nothing more than minors. I altered them and I’m here not for complaint but for thanks. Thanks a lot!
Jack Joye
5.0
I guess I couldn't graduate without this service. Thank you for writing all your assignments.
Cherry Zhao
5.0
A company whose not only prices are affordable but it issues original data as well. I love to suggest this service to friends!
Gabriel Sven
5.0
Well worth finding this website and this is an awesome company. Thank you!
Next Articles
- Takeda Pharmaceutical Company (C): The Future Of Takeda Bcg Matrix
- Amgen Inc.: Pursuing Innovation And Imitation? (A) Bcg Matrix
- Orthoteks USA (C) Bcg Matrix
- Drug Eluting Stents: A Paradigm Shift In The Medical Device Industry Bcg Matrix
- American Cyanamid (B): Management's Response To The (A) Case Bcg Matrix
- Abbott Laboratories And HUMIRA: Launching A Blockbuster Drug (Condensed) Bcg Matrix
- Knowledge Creation At Eisai Co., Ltd. Bcg Matrix
- Orthoteks USA (B2) Bcg Matrix
- Building A Scalable Business With Small Holder Farmers In Kenya: Honey Care's Beekeeping Model Bcg Matrix
- Zoll Medical Corp. (A) Bcg Matrix
Previous Articles
- Crestor Bcg Matrix
- Amgen Inc.'s Epogen Commercializing The First Biotech Blockbuster Drug Bcg Matrix
- Building The Virtual Lab: Global Licensing And Partnering At Merck Bcg Matrix
- The Highly Regulated German Medical Supplies Industry (A) Bcg Matrix
- At A Crossroads: The Strategic Dilemma At PENPOL Bcg Matrix
- Zandu Pharmaceutical Works: The Takeover Bid (A) Bcg Matrix
- Invitrogen (A) Bcg Matrix
- Takeda Pharmaceutical Company (B): The Millennium Acquisition Bcg Matrix
- Molecular Insight Pharmaceuticals: Integrated Strategy For A Development Stage Molecular Medicine Company Bcg Matrix
- Merck & Co., Inc.: Addressing Third World Needs (D) Bcg Matrix
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!